Hyphens Pharma International Ltd. · SGX:1J5
Hyphens Pharma International — INVEST Fair 2018
30 slides from Hyphens Pharma International's conference presentation, Aug 29, 2018
Slide 1: General Announcement: Corporate Presentation at INVEST Fair 2018
General Announcement::Corporate Presentation at INVEST Fair 2018 Page 1 of 1 General Announcement::Corporate Presentation at INVEST Fair 2018 Issuer & Securities Issuer/ Manager HYPHENS PHARMA INTERNATIONAL LIMITED Securities HYPHENS PHARMA INTL LIMITED - SG1EE4000006 - 1J5 Stapled Security No Annou
Slide 2: Hyphens Pharma International Limited
Hyphens Pharma International Limited 凯帆药剂国际有限公司 A Leading Specialty Pharmaceuticals & Consumer Healthcare Group listed on
Slide 3: Disclaimer
Disclaimer This presentation has been prepared by Hyphens Pharma International Limited (the "Company" and, together with its subsidiaries, the "Group"). This content in this presentation is being furnished to you on a confidential basis and solely for your information and neither this presentation n
Slide 4: Company Overview
Company Overview
Slide 5: Evolution of our Business
Evolution of our Business Medical Hypermart • Listed on and Digital Specialty Pharma Principals Proprietary Business Segments Brands • Acquired full control 2018 of Philippines 2017 subsidiary • Acquired 25.0% of 2016 • Expanded into • Expand presence • Acquired a product Hyphens Pharma Malaysia for
Slide 6: Who We Are Today
Who We Are Today One of Singapore’s leading specialty pharmaceutical and consumer healthcare groups with an established presence in ASEAN FY17 Revenue Breakdown by Business Segments FY17 Revenue Breakdown by Geography Others Malaysia 5.1% 4.7% Medical hypermart and digital Specialty 35.0% pharma Sin
Slide 7: Key Strengths
bs a J Wily, | Key Strengths
Slide 8: Key Strengths
Key Strengths One of Singapore’s leading specialty pharmaceutical and consumer healthcare groups 1 with an established presence in ASEAN 2 Strong regulatory capabilities with high barriers to entry International portfolio of specialty pharmaceutical products, with strong principal 3 relationships 4
Slide 9: Leading specialty pharmaceutical and consumer healthcare group with ASEAN presence
One of Singapore’s leading specialty pharmaceutical and consumer 1 healthcare groups with an established presence in ASEAN + One of Singapore’s most established companies in the pharmaceutical and consumer healthcare space + Heritage Pan-Malayan brand with a history of more than 70 years + Establish
Slide 10: Well-positioned to benefit from increased healthcare expenditure
1 Well-positioned to benefit from increased healthcare expenditure GDP growth from 2007 to 20151 + ASEAN combined GDP increased from US$0.58 trillion to (2007 = 100) US$2.55 trillion from 1999 to 2016 CAGR + GDP per capita increased from US$1,135 to US$4,021 over the 250 12.1% same period + In tande
Slide 11: Strong regulatory capabilities with high barriers to entry
2 Strong regulatory capabilities with high barriers to entry Marketing is subject to strict regulations and product must be registered Strong Regulatory Capabilities Separate registration for each product in different markets + High Barriers Requirements for operating licences such as the Good Distr
Slide 12: International portfolio with strong principal relationships
3 International portfolio with strong principal relationships + Strong relationships with principals, some for more than 20 years + Internationally known portfolio of products with leading pharmaceutical companies Regional Presence Our principals and more… Strong Regulatory Our products Capabilities
Slide 13: Strong sales and marketing capabilities
4 Strong sales and marketing capabilities Our Regional Sales & Marketing Team Specialty Pharma Principals + Dedicated sales and marketing team THE PHILIPPINES VIETNAM + Requires significant domain knowledge 1552 27 and understanding the needs of the doctors to ensure the dissemination of accurate pr
Slide 14: Strong sales and marketing capabilities
4 Strong sales and marketing capabilities Medical Hypermart and Digital + Dedicated sales and marketing team + New digital initiative of the Virtual Hypermart Allows customers to place orders at their convenience Improves productivity and scalable model Customer base of difficult-to-access phy
Slide 15: Ownership of a range of proprietary products and brands
5 Ownership of a range of proprietary products and brands Dermatology + Marketed primarily through medical professionals, including general practitioners, dermatologists, paediatricians and pharmacists 14
Slide 16: Ownership of a range of proprietary products and brands
5 Ownership of a range of proprietary products and brands Health Supplements + Marketed directly to consumers in Singapore via retail channels, including major retail pharmacies Our proprietary products allows us to: + Determine the commercialisation strategy; + Access retail distribution channels v
Slide 17: Highly experienced and committed management team
6 Highly experienced and committed management team Ms. Fang Lee Wei Chief Financial Officer Mr. Lim See Wah Mr. Tan Chwee Choon Chairman, Executive Director & CEO Executive Director + With more than 25 years of + Responsible for our Indochina Mr. John Leong experience in the pharmaceutical operation
Slide 18: Growth Strategies
Growth Strategies
Slide 19: Growth Strategies
Growth Strategies 1 Expand and strengthen product range Maintain our growth momentum through scaling our presence in markets that 2 we operate in and expansion to new geographical markets Enhance our online platform and further leverage on it to increase revenue 3 and manage costs 4 Expand through a
Slide 20: Expand and strengthen product range
1 Expand and strengthen product range Proprietary Brands Specialty Pharmaceuticals + Add to product portfolio for existing + Expand product range principals Strategy + Launch another 5 products in 2018 + Explore commercial opportunities with new principals + Patent-pending next generation line of Ce
Slide 21: Maintain our growth momentum
2 Maintain our growth momentum + Scale up presence in existing markets such as Vietnam, Malaysia, Indonesia and the Philippines Expand marketing and distribution network and/or leverage on existing channels + Expand into new markets Registration of dermocosmetic products in ASEAN, as well as the
Slide 22: Enhance our online platform to increase revenue and manage costs
Enhance our online platform and further leverage on it to 3 increase revenue and manage costs Marketing to convert existing customers to transact online Active promotion + Promotional rates + Loyalty programme Virtual Capitalise on first mover advantage to establish an online platform Hypermart Addi
Slide 23: Expand through acquisitions, joint ventures or strategic alliances
Expand through acquisitions, joint ventures or strategic 4 alliances Acquisitions, JVs, Strategic Alliances synergistic to our existing business Enhance Capability In Existing Product Acquisitions Markets or New Markets + Focus on dermocosmetic and health + Acquisition of customers based in a market
Slide 24: Enhance our infrastructure to support business growth
5 Enhance our infrastructure to support business growth Integrated Facility Office Warehouse Packaging Facility 23
Slide 25: Financial Highlights
FINANCIAL HIGHLIGHTS
Slide 26: Revenue (S$'m)
1 Revenue (S$’m) 3-year audited Half-year unaudited 113.2 101.0 S$4m 7.0% 78.3 61.5 57.5 FY2015 FY2016 FY2017 1H2017 1H2018 25
Slide 27: Profit after tax (S$'m)
2 Profit after tax (S$’m) 3-year audited Half-year unaudited 6.1 S$0.9m 14.3% S$0.4m 5.1 5.2 4.3 -10.0% 3.8 3.4 1H2017 1H2018 1H2018 (without FY2015 FY2016 FY2017 IPO expenses) 26
Slide 28: Revenue by Business Segment (S$'m)
3 Revenue by Business Segment (S$’m) 1H2018 1H2017 18.9, 31% 20.1, 35% 35.9, 58% 31.0, 54% 6.8, 11% 6.3, 11% SPECIALTY PHARMA PRINCIPALS PROPRIETARY BRANDS MEDICAL HYPERMART & DIGITAL 27
Slide 29: Group Financial Half Year Overview
4 Group Financial Half Year Overview S$’mil 1H2018 1H2017 Change % Revenue 61.5m 57.5m 7.0% EBITDA 4.8m 5.1m -5.1% Profit before tax 4.4m 4.6m -4.4% Profit after tax 3.4m 3.8m -10.0% EPS (cents) 1.14 1.26 -9.5% NAV per share 12.40 6.28 97.5% (cents) S$’000 1H2018 1H2017 Change % Without IPO expenses
Slide 30: | 138 Joo Seng Road 3 rd Floor | Singapore 368361 | | +65
| 138 Joo Seng Road 3rd Floor | Singapore 368361 | | +65 6388 8551 | connect@hyphens.com.sg | | www.hyphens.com.sg | | SINGAPORE | VIETNAM | | MALAYSIA | PHILIPPINES | INDONESIA | 29